Bora Pharmaceuticals Co (TPE:6472) Piotroski F-Score: 5 (As of Jul. 05, 2026) — Near Median


TPE:6472 Bora Pharmaceuticals Co Ltd TPE:6472
87 GF Score
Price NT$439.50
GF Value NT$716.94
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Bora Pharmaceuticals Co Piotroski F-Score?

Bora Pharmaceuticals Co TPE:6472 +1.74% 87 Piotroski F-Score is 5 as of Jul. 05, 2026, which is at its 10-year median of 5.00. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$716.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 979 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 61.39% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bora Pharmaceuticals Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Bora Pharmaceuticals Co's Piotroski F-Score or its related term are showing as below:

TPE:6472' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of Bora Pharmaceuticals Co was 7. The lowest was 4. And the median was 5.

Bora Pharmaceuticals Co  (TPE:6472) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Bora Pharmaceuticals Co Piotroski F-Score Related Terms


Bora Pharmaceuticals Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Bora Pharmaceuticals Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bora Pharmaceuticals Co Piotroski F-Score Chart

Bora Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 6.00 5.00 5.00

Bora Pharmaceuticals Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 5.00 5.00

TPE:6472 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bora Pharmaceuticals Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Bora Pharmaceuticals Co's Piotroski F-Score falls into.


TPE:6472
87GF Score
Bora Pharmaceuticals Co Ltd TPE:6472
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 1399.273 + 616.669 + 633.61 + 331.759 = NT$2,981 Mil.
Cash Flow from Operations was 1344.957 + 1360.014 + 569.503 + 1229.115 = NT$4,504 Mil.
Revenue was 4479.585 + 4867.785 + 4806.145 + 4860.654 = NT$19,014 Mil.
Gross Profit was 1889.497 + 2019.383 + 2171.873 + 1772.261 = NT$7,853 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(45509.645 + 46758.653 + 41963.962 + 43741.05 + 44714.187) / 5 = NT$44537.4994 Mil.
Total Assets at the begining of this year (Dec24) was NT$45,510 Mil.
Long-Term Debt & Capital Lease Obligation was NT$12,505 Mil.
Total Current Assets was NT$19,338 Mil.
Total Current Liabilities was NT$13,321 Mil.
Net Income was 716.137 + 1085.321 + 1705.935 + 345.122 = NT$3,853 Mil.

Revenue was 2857.493 + 4417.206 + 5027.239 + 5124.686 = NT$17,427 Mil.
Gross Profit was 1505.99 + 1967.221 + 2337.39 + 1979.935 = NT$7,791 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(25134.173 + 30659.544 + 43352.789 + 43574.409 + 45509.645) / 5 = NT$37646.112 Mil.
Total Assets at the begining of last year (Dec23) was NT$25,134 Mil.
Long-Term Debt & Capital Lease Obligation was NT$15,070 Mil.
Total Current Assets was NT$23,377 Mil.
Total Current Liabilities was NT$13,808 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bora Pharmaceuticals Co's current Net Income (TTM) was 2,981. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bora Pharmaceuticals Co's current Cash Flow from Operations (TTM) was 4,504. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=2981.311/45509.645
=0.06550943

ROA (Last Year)=Net Income/Total Assets (Dec23)
=3852.515/25134.173
=0.15327797

Bora Pharmaceuticals Co's return on assets of this year was 0.06550943. Bora Pharmaceuticals Co's return on assets of last year was 0.15327797. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Bora Pharmaceuticals Co's current Net Income (TTM) was 2,981. Bora Pharmaceuticals Co's current Cash Flow from Operations (TTM) was 4,504. ==> 4,504 > 2,981 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=12505.181/44537.4994
=0.2807787

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=15069.854/37646.112
=0.40030306

Bora Pharmaceuticals Co's gearing of this year was 0.2807787. Bora Pharmaceuticals Co's gearing of last year was 0.40030306. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=19337.605/13320.926
=1.45167123

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=23377.193/13807.98
=1.69302049

Bora Pharmaceuticals Co's current ratio of this year was 1.45167123. Bora Pharmaceuticals Co's current ratio of last year was 1.69302049. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Bora Pharmaceuticals Co's number of shares in issue this year was 135.275. Bora Pharmaceuticals Co's number of shares in issue last year was 135.296. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=7853.014/19014.169
=0.41300853

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=7790.536/17426.624
=0.44704792

Bora Pharmaceuticals Co's gross margin of this year was 0.41300853. Bora Pharmaceuticals Co's gross margin of last year was 0.44704792. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=19014.169/45509.645
=0.41780526

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=17426.624/25134.173
=0.69334384

Bora Pharmaceuticals Co's asset turnover of this year was 0.41780526. Bora Pharmaceuticals Co's asset turnover of last year was 0.69334384. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bora Pharmaceuticals Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Bora Pharmaceuticals Co (TPE:6472) has a Piotroski F-Score of 5 as of Jul. 05, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bora Pharmaceuticals Co and its competitors. This is near median its historical median of 5.00. Over the past decade, Bora Pharmaceuticals Co's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #378 out of 979 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Bora Pharmaceuticals Co's Piotroski F-Score too high?
Bora Pharmaceuticals Co's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Bora Pharmaceuticals Co's value of 5 is 0% at this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #378 out of 979 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #378 out of 979 companies for Piotroski F-Score. This puts Bora Pharmaceuticals Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Bora Pharmaceuticals Co's value of 5 is 0% at this benchmark. Historically, Bora Pharmaceuticals Co's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Bora Pharmaceuticals Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$716.94, compared to a current price of NT$439.50 — trading 38.7% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current Piotroski F-Score is 5 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?

Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$439.50 is trading 38.7% below its estimated GF Value™ of NT$716.94. GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for TPE:6472:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: NT$716.94 vs. price of NT$439.50 (38.7% below fair value)
  • GF Score™: 87/100 with 4 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#378 of 979)

No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bora Pharmaceuticals Co Business Description

Address No. 2, Aly. 36, Lane 26, Ruiguang Road, 6th Floor, Neihu District, Taipei, TWN, 114
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score

Get the complete analysis for TPE:6472

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$439.50
Price
NT$716.94
GF Value